Lithium Long COVID Dose-finding Study

Completed · Phase 1

Conditions studied: Long COVID

In brief

This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.

Key facts

Study ID
NCT06108297
Run by
State University of New York at Buffalo
People needed
5
Starts
2023-10-12
Expected to finish
2024-05-02
Last updated by the study team
2024-10-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.